These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
171 related articles for article (PubMed ID: 35319404)
21. Review of recent molecular landscape knowledge of gastric cancer. Shimizu D; Kanda M; Kodera Y Histol Histopathol; 2018 Jan; 33(1):11-26. PubMed ID: 28447336 [TBL] [Abstract][Full Text] [Related]
22. Discovery and Validation of Salivary Extracellular RNA Biomarkers for Noninvasive Detection of Gastric Cancer. Li F; Yoshizawa JM; Kim KM; Kanjanapangka J; Grogan TR; Wang X; Elashoff DE; Ishikawa S; Chia D; Liao W; Akin D; Yan X; Lee MS; Choi R; Kim SM; Kang SY; Bae JM; Sohn TS; Lee JH; Choi MG; Min BH; Lee JH; Kim JJ; Kim Y; Kim S; Wong DTW Clin Chem; 2018 Oct; 64(10):1513-1521. PubMed ID: 30097497 [TBL] [Abstract][Full Text] [Related]
23. An overview of the multifaceted roles of miRNAs in gastric cancer: Spotlight on novel biomarkers and therapeutic targets. Wu X; Shen J; Xiao Z; Li J; Zhao Y; Zhao Q; Cho CH; Li M Biochem Pharmacol; 2019 May; 163():425-439. PubMed ID: 30857828 [TBL] [Abstract][Full Text] [Related]
24. Identification and functional characterization of microRNAs reveal a potential role in gastric cancer progression. Li CY; Liang GY; Yao WZ; Sui J; Shen X; Zhang YQ; Peng H; Hong WW; Ye YC; Zhang ZY; Zhang WH; Yin LH; Pu YP Clin Transl Oncol; 2017 Feb; 19(2):162-172. PubMed ID: 27173517 [TBL] [Abstract][Full Text] [Related]
25. Exosomal miRNAs from Peritoneum Lavage Fluid as Potential Prognostic Biomarkers of Peritoneal Metastasis in Gastric Cancer. Tokuhisa M; Ichikawa Y; Kosaka N; Ochiya T; Yashiro M; Hirakawa K; Kosaka T; Makino H; Akiyama H; Kunisaki C; Endo I PLoS One; 2015; 10(7):e0130472. PubMed ID: 26208314 [TBL] [Abstract][Full Text] [Related]
26. The role of microRNAs in carcinogenesis and the utility of microRNA determination in diagnosis of gastric cancer development. Cholewinski G; Waluga M J Physiol Pharmacol; 2022 Dec; 73(6):. PubMed ID: 37087560 [TBL] [Abstract][Full Text] [Related]
27. Advances in molecular biomarkers for gastric cancer: miRNAs as emerging novel cancer markers. Wu HH; Lin WC; Tsai KW Expert Rev Mol Med; 2014 Jan; 16():e1. PubMed ID: 24456939 [TBL] [Abstract][Full Text] [Related]
28. microRNA analysis of gastric cancer patients from Saudi Arabian population. Bibi F; Naseer MI; Alvi SA; Yasir M; Jiman-Fatani AA; Sawan A; Abuzenadah AM; Al-Qahtani MH; Azhar EI BMC Genomics; 2016 Oct; 17(Suppl 9):751. PubMed ID: 27766962 [TBL] [Abstract][Full Text] [Related]
29. MiR-199a/b-3p inhibits gastric cancer cell proliferation via down-regulating PAK4/MEK/ERK signaling pathway. Zeng B; Shi W; Tan G BMC Cancer; 2018 Jan; 18(1):34. PubMed ID: 29304764 [TBL] [Abstract][Full Text] [Related]
30. Three-microRNA signature identified by bioinformatics analysis predicts prognosis of gastric cancer patients. Zhang C; Zhang CD; Ma MH; Dai DQ World J Gastroenterol; 2018 Mar; 24(11):1206-1215. PubMed ID: 29568201 [TBL] [Abstract][Full Text] [Related]
31. Long noncoding RNA SPRY4-IT1 predicts poor patient prognosis and promotes tumorigenesis in gastric cancer. Peng W; Wu G; Fan H; Wu J; Feng J Tumour Biol; 2015 Sep; 36(9):6751-8. PubMed ID: 25835973 [TBL] [Abstract][Full Text] [Related]
32. Three dysregulated microRNAs in serum as novel biomarkers for gastric cancer screening. Wang H; Wang L; Wu Z; Sun R; Jin H; Ma J; Liu L; Ling R; Yi J; Wang L; Bian J; Chen J; Li N; Yuan S; Yun J Med Oncol; 2014 Dec; 31(12):298. PubMed ID: 25367852 [TBL] [Abstract][Full Text] [Related]
33. MicroRNAs: promising chemoresistance biomarkers in gastric cancer with diagnostic and therapeutic potential. Matuszcak C; Haier J; Hummel R; Lindner K World J Gastroenterol; 2014 Oct; 20(38):13658-66. PubMed ID: 25320504 [TBL] [Abstract][Full Text] [Related]
34. Gastric Juice MicroRNAs as Potential Biomarkers for Screening Gastric Cancer: A Systematic Review. Virgilio E; Giarnieri E; Giovagnoli MR; Montagnini M; Proietti A; D'Urso R; Mercantini P; Balducci G; Cavallini M Anticancer Res; 2018 Feb; 38(2):613-616. PubMed ID: 29374683 [TBL] [Abstract][Full Text] [Related]
35. Role of miR‑34 in gastric cancer: From bench to bedside (Review). Xiong S; Hu M; Li C; Zhou X; Chen H Oncol Rep; 2019 Nov; 42(5):1635-1646. PubMed ID: 31432176 [TBL] [Abstract][Full Text] [Related]
36. Downregulation of microRNA-376a in Gastric Cancer and Association with Poor Prognosis. Zhang C; Liang Y; Ma MH; Wu KZ; Zhang CD; Dai DQ Cell Physiol Biochem; 2018; 51(5):2010-2018. PubMed ID: 30522118 [TBL] [Abstract][Full Text] [Related]
37. Recent advances in the molecular diagnostics of gastric cancer. Kanda M; Kodera Y World J Gastroenterol; 2015 Sep; 21(34):9838-52. PubMed ID: 26379391 [TBL] [Abstract][Full Text] [Related]
38. MicroRNAs in gastric cancer: from bench to bedside. Hu ML; Xiong SW; Zhu SX; Xue XX; Zhou XD Neoplasma; 2019 Mar; 66(2):176-186. PubMed ID: 30509106 [TBL] [Abstract][Full Text] [Related]
39. TEAD1/4 exerts oncogenic role and is negatively regulated by miR-4269 in gastric tumorigenesis. Zhou Y; Huang T; Zhang J; Wong CC; Zhang B; Dong Y; Wu F; Tong JHM; Wu WKK; Cheng ASL; Yu J; Kang W; To KF Oncogene; 2017 Nov; 36(47):6518-6530. PubMed ID: 28759040 [TBL] [Abstract][Full Text] [Related]
40. Incorporating molecular biomarkers into clinical practice for gastric cancer. Nakamura S; Kanda M; Kodera Y Expert Rev Anticancer Ther; 2019 Sep; 19(9):757-771. PubMed ID: 31437076 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]